A Agilent Technologies Inc.

Agilent LC/MS Instruments Receive ACT Labels from My Green Lab

(NYSE: A) announced today that both the and the systems have earned the highly-respected Accountability, Consistency and Transparency (ACT) Label from , a nonprofit organization dedicated to improving the sustainability of scientific research.

“Agilent’s mission is to provide trusted answers and insights that advance the quality of life, and sustainability is an important part of achieving that mission,” said Sudharshana Seshadri, vice president of Agilent’s Mass Spectrometry Division. “We strive to consistently improve our sustainability through our innovative products and technologies that address complex issues in a sustainable way.”

Agilent is committed to helping labs meet their sustainability goals by including environmental considerations as drivers for innovation. In a recent global , 87% of lab managers indicated that sustainability goals are important in running their labs. Additionally, 68% reported that further work is required to achieve their sustainability goals.

“Partnering with My Green Lab has provided us the opportunity to work with an expert in this field,” said Darlene Solomon, senior vice president, and chief technology officer at Agilent. “We chose them for their holistic approach to sustainability and their understanding of the scientific interconnectivity across the laboratory, from chemicals to instruments to the environment itself.”

To celebrate these green instruments and also acknowledge Agilent has kicked off a Plant a Tree program with customers and employees, with the goal to plant over 1,500 trees in Brazil, China, Colombia, Kenya and Tanzania, Mexico, and the United States, by the end of September 2021.

Additional instruments that received My Green Lab ACT Labels in 2020 include the Agilent 1220 Infinity II LC System, the 1260 Infinity II LC System, and the 1290 Infinity II LC System.

The ACT Label criteria, known as the Environmental Impact Factor (EIF) criteria, were developed with industry input. Agilent instruments that have received the ACT Label include sustainability features such as reduced energy consumption, less material used per product, smaller packaging (improving shipping sustainability), as well as sustainable (recycled) product and packaging. All enabling customers to make better informed as well as sustainable choices for their lab.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Information about Agilent is available at .

EN
22/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch